# Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

> **NCT05401071** · PHASE2,PHASE3 · RECRUITING · sponsor: **Huashan Hospital** · enrollment: 2442 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **OTHER:** Short Regimen with Rifapentine 10mg/kg
- **COMBINATION_PRODUCT:** Standardized Regimen
- **OTHER:** Short Regimen with Rifapentine 15mg/kg
- **OTHER:** Short Regimen with Rifapentine 20mg/kg

## Key facts

- **NCT ID:** NCT05401071
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-13
- **Primary completion:** 2024-10-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 2442 (ESTIMATED)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05401071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05401071, "Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05401071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*